Brain-permeantmGlu2/3 receptor agonists are particularly promising for the experimental treatmentof Parkinson's disease for the ability to enhance striatal levels of GDNF(present data) and TGF-β [12], [14]. The gene discussed is GDNF; the disease is Parkinson disease.